Prenatal Alcohol Biomarker Study in Uruguay

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT02600624
Collaborator
(none)
1,412
2
34.4
706
20.5

Study Details

Study Description

Brief Summary

The purpose of this study is to examine the association between maternal alcohol use and newborn phosphatidylethanol (PEth) levels in their newborn.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The goal of the proposed research study is to examine the association between maternal alcohol use and newborn phosphatidylethanol (PEth) levels in their newborn children, in a country (Uruguay) where significant alcohol use is common during pregnancy. Maternal alcohol biomarker assays will include ethyl glucuronide (EtG) in hair and nails and PEth in blood obtained at the time of delivery. Newborn umbilical cord and routine 48 hour heel stick blood will be collected to assess newborn PEth levels. Maternal biomarker levels will be compared to patient self-reported alcohol use. This proposed design is a cross-sectional study that will include 1,800 women 18 years and older and their newborns. Women who are admitted to one of two selected public health care hospitals in Montevideo, Uruguay (Hospital Pereira Rossell and Servicio Medico Integral) for obstetrical care will be recruited to participate in the study. Power estimates suggest that 1,800 maternal/infant pairs will give us sufficient power (>90%) to estimate the predictive validity of this biomarker as a routine newborn screening test.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    1412 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay
    Actual Study Start Date :
    Aug 18, 2016
    Actual Primary Completion Date :
    Jul 1, 2019
    Actual Study Completion Date :
    Jul 1, 2019

    Arms and Interventions

    Arm Intervention/Treatment
    Participants

    Women who are in active labor and their newborn infants.

    Outcome Measures

    Primary Outcome Measures

    1. Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay [The maternal questionnaire will occur during the 48 hrs following childbirth]

      Conduct a formative assessment of the prevalence and patterns of maternal alcohol consumption during pregnancy and the relationship of these reported patterns to maternal biomarker levels (EtG in hair and nails and PEth in blood) in a large sample (n=1800) of pregnant women in Montevideo, Uruguay.

    Secondary Outcome Measures

    1. Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay [PEth and EtG Biomarkers from the mothers and newborns will be collected during the 48 hrs after childbirth.]

      Biomarkers will be collected to determine the correlations between maternal self-report of alcohol consumption, maternal alcohol biomarker levels and newborn PEth concentration levels at birth. It will also help identify the sensitivity and specificity of PEth and the predictive value of newborn PEth levels; and the half-life and window of detection of PEth in newborns by examining the kinetics of PEth elimination.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Inclusion criteria for experimental group (n=1,800)

    • Pregnant women 18 years and older

    • Admitted in active labor as well as their newborn child

    • Well enough to participate in the research interview

    • Able to provide fingernail, hair, and blood spot samples

    • All subjects must have given signed, informed consent prior to registration

    Exclusion Criteria:
    • Not meeting the appropriate inclusion criteria or providing consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Northwestern Memorial Hospital Chicago Illinois United States 60611
    2 Clínica Ginecología/Obstétrica del Hospital General de las Fuerzas Armadas de Uruguay Montevideo Uruguay

    Sponsors and Collaborators

    • Northwestern University

    Investigators

    • Principal Investigator: Michael Fleming, MD, MPH, Northwestern University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Michael Fleming, Professor in Psychiatry and Behavioral Sciences and Family and community Medicine, Northwestern University
    ClinicalTrials.gov Identifier:
    NCT02600624
    Other Study ID Numbers:
    • STU00200504
    First Posted:
    Nov 9, 2015
    Last Update Posted:
    Apr 3, 2020
    Last Verified:
    Apr 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 3, 2020